The first phase 3 trial of an SGLT2 inhibitor in children and young people with type 2 diabetes shows that dapagliflozin significantly improves their glucose control – as long as they remember to take it.
The virtual CHIEF-HF trial has demonstrated a significant positive effect of canagliflozin on heart failure symptoms without the need for in-person clinic visits, the investigators report in Nature Medicine.